# Implementing Prevention of Venous Thromboembolism for Ambulatory Patients with Cancer (PREVenT-APC)

> **NIH NIH K23** · NORTHWESTERN UNIVERSITY · 2023 · $166,998

## Abstract

PROJECT SUMMARY
Background: Venous thromboembolism (VTE) is one of the most common causes of death in cancer
patients. Guidelines recommend the use of VTE risk-stratification to identify ambulatory patients with
cancer at high-risk of VTE who may benefit from primary VTE prevention with prophylactic
anticoagulation. However, our preliminary data suggest that VTE risk assessment and primary
prophylaxis are substantially underused.
Aims and Methods: The overall objective of this project is to develop a feasible, effective, and
sustainable implementation strategy to promote the uptake into clinical practice of evidence-based
guidelines for VTE prevention in patients with cancer. The Specific Aims of this proposal are to:
Aim 1: Conduct formative research to develop an implementation strategy (PREVenT-APC)
 promoting the uptake in clinical practice of a guideline-recommended, risk-based approach
 to primary VTE prevention for ambulatory patients with cancer;
Aim 2: Using a randomized trial, assess effectiveness of the refined PREVenT-APC strategy as
 compared with usual care, to start and maintain thromboprophylaxis for identified high-risk
 patients with cancer; and
Aim 3: Explore implementation outcomes and the contextual factors associated with variability in
 adoption, fidelity, effectiveness, and acceptability of the PREVenT-APC implementation
strategy.
To carry out the study, I will develop the PREVenT-APC strategy and conduct usability testing to refine
the strategy (Aim 1); test the PREVenT-APC strategy via a randomized trial (Aim 2); and, using mixed
methods, evaluate additional implementation outcomes, and explore variability in outcomes of the
PREVenT-APC strategy (Aim 3).
Career Development and Future Work: Through the objectives of the K23 Mentored Career
Development Award, I will acquire advanced knowledge and apply skills in mixed method research,
behavioral intervention clinical trial design, and dissemination and implementation science, which will
further my goal of becoming an independent physician scientist with expertise in developing,
implementing, and evaluating strategies to improve cross-specialty hematology care. The study findings
will serve as a foundation for future R-level proposals to tailor and test adaptations and dissemination of
the PREVenT-APC implementation strategy in different settings. Ultimately, the long-term goal of the
proposed research is to reduce VTE and improve outcomes for patients with cancer.

## Key facts

- **NIH application ID:** 10659200
- **Project number:** 5K23HL157758-02
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Karlyn Martin
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $166,998
- **Award type:** 5
- **Project period:** 2022-07-15 → 2023-08-12

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10659200

## Citation

> US National Institutes of Health, RePORTER application 10659200, Implementing Prevention of Venous Thromboembolism for Ambulatory Patients with Cancer (PREVenT-APC) (5K23HL157758-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10659200. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*